AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3076790 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose enprofylline (1 mg/kg bolus and 500 micrograms/kg/hour infusion)
Number of subjects: 14
Study 3076790 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (5 mg/kg bolus and 500 micrograms/kg/hour infusion)
Number of subjects: 14
Study 3076790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30823822 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual training targeting the English /æ-ɛ/ contrast, with a condition that shifted the perceptual boundary toward /æ/.
Number of subjects: 40
Study 30823822 — intervention group
Group type: COMPARATOR
Intervention: Perceptual training targeting the English /æ-ɛ/ contrast, with a condition that shifted the perceptual boundary toward /ɛ/.
Number of subjects: 40
Study 30085996 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-friendly smartphone launcher
Number of subjects: 50
Study 30085996 — intervention group
Group type: COMPARATOR
Intervention: Standard Android smartphone launcher
Number of subjects: 50
Study 26888759 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended intervention (33 months) with web-based materials and Facebook engagement
Number of subjects: 0
Study 26888759 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 months)
Number of subjects: 0
Study 24673675 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call follow-up by a nurse
Number of subjects: 120
Study 24673675 — intervention group
Group type: COMPARATOR
Intervention: Placebo call (patient satisfaction survey)
Number of subjects: 120
Study 24673675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no call)
Number of subjects: 120
Study 24673675 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (intervention, placebo, control)
Number of subjects: 120
Study 24673675 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analysis of the intervention
Number of subjects: 120
Study 22094911 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 348
Study 22094911 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 348
Study 21050476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin 10/20 mg (EZ/Simva)
Number of subjects: 618
Study 21050476 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg (Rosuva)
Number of subjects: 618
Study 17577218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone 35 mg/m² intravenously every 3 weeks
Number of subjects: 82
Study 17577218 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone 14 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily
Number of subjects: 82
Study 17577218 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-line crossover treatment
Number of subjects: 82
Study 17577218 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 82
Study 15037444 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 99
Study 15037444 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 99
Study 15037444 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 99
Study 11358775 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet
Number of subjects: 3764
Study 11358775 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary Card
Number of subjects: 3764
Study 11358775 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery access times)
Number of subjects: 3764
Study 9479724 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 120
Study 9479724 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 120
Study 8058226 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine jelly
Number of subjects: 203
Study 8058226 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate
Number of subjects: 203
Study 3133709 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg trazodone nocte
Number of subjects: 182
Study 3133709 — intervention group
Group type: COMPARATOR
Intervention: 50 mg trazodone t.d.s.
Number of subjects: 182
Study 3133709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 182
Study 3133709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing regimens
Number of subjects: 182
Study 31834852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with low VZ-IgG (<100 mIU/dL)
Number of subjects: 350
Study 31834852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with high VZ-IgG (>100 mIU/dL)
Number of subjects: 350
Study 31834852 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns with low VZ-IgG
Number of subjects: 350
Study 31834852 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns with high VZ-IgG
Number of subjects: 350
Study 31834852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with past VZV infection
Number of subjects: 350
Study 29298706 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive pancreatoduodenectomy (MIPD)
Number of subjects: 136
Study 29298706 — intervention group
Group type: COMPARATOR
Intervention: Open pancreatoduodenectomy
Number of subjects: 136
Study 27178002 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (HF-rTMS) of the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 18
Study 27178002 — intervention group
Group type: COMPARATOR
Intervention: Sham-rTMS
Number of subjects: 18
Study 26412680 — intervention group
Group type: EXPERIMENTAL
Intervention: TANDEMplus communication training
Number of subjects: 254
Study 26412680 — intervention group
Group type: COMPARATOR
Intervention: TANDEM communication training
Number of subjects: 254
Study 24021501 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG neurofeedback
Number of subjects: 41
Study 24021501 — intervention group
Group type: COMPARATOR
Intervention: Placebo neurofeedback
Number of subjects: 41
Study 21399651 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-positive men undergoing ICSI
Number of subjects: 916
Study 21399651 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-positive men undergoing IVF
Number of subjects: 916
Study 21399651 — intervention group
Group type: COMPARATOR
Intervention: HBV-negative men undergoing ICSI
Number of subjects: 916
Study 21399651 — intervention group
Group type: COMPARATOR
Intervention: HBV-negative men undergoing IVF
Number of subjects: 916
Study 18804577 — intervention group
Group type: EXPERIMENTAL
Intervention: RhBMP-7
Number of subjects: 30
Study 18804577 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 30
Study 16831143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day for 3 months
Number of subjects: 90
Study 16831143 — intervention group
Group type: COMPARATOR
Intervention: Control (immediate surgery)
Number of subjects: 90
Study 12746164 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment (daily iron administration)
Number of subjects: 94
Study 12746164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment (iron administration 2 days a week)
Number of subjects: 94
Study 12746164 — intervention group
Group type: COMPARATOR
Intervention: Control group (23 children with compatible age and gender distribution)
Number of subjects: 94
Study 10588216 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/day)
Number of subjects: 17
Study 10588216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8724062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg/day in one daily dose)
Number of subjects: 210
Study 8724062 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (40 mg/kg/day divided into 3 daily doses)
Number of subjects: 210
Study 1927862 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 34
Study 1927862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7037030 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 10
Study 7037030 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 10
Study 7037030 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 10
Study 31446847 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport directly to a comprehensive stroke center for intravenous thrombolysis and endovascular therapy
Number of subjects: 600
Study 31446847 — intervention group
Group type: COMPARATOR
Intervention: Transport to a primary stroke center for intravenous thrombolysis and subsequent transport to a comprehensive stroke center for endovascular therapy if needed
Number of subjects: 600
Study 31519320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily for up to 24 months
Number of subjects: 940
Study 31519320 — intervention group
Group type: COMPARATOR
Intervention: Placebo for up to 24 months
Number of subjects: 940
Study 31519320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 940
Study 31519320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 940
Study 26423728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 26423728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26331961 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about n-3 and CLA (n=325)
Number of subjects: 647
Study 26331961 — intervention group
Group type: COMPARATOR
Intervention: No information about n-3 and CLA (n=322)
Number of subjects: 647
Study 26331961 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (n=647)
Number of subjects: 647
Study 24954228 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m² and cisplatin 75 mg/m² on day 1 (arm A)
Number of subjects: 153
Study 24954228 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine 80 mg/m² on days 1 and 8 (first cycle 60 mg/m²) and cisplatin 80 mg/m² on day 1 (arm B)
Number of subjects: 153
Study 22642740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose atenolol plus fixed dose losartan
Number of subjects: 26
Study 22642740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22642740 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (atenolol + losartan and placebo)
Number of subjects: 26
Study 22642740 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 26
Study 19788366 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Number of subjects: 242
Study 19788366 — intervention group
Group type: COMPARATOR
Intervention: Present‐Centered Therapy
Number of subjects: 242
Study 18087186 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified automated algorithm
Number of subjects: 77
Study 18087186 — intervention group
Group type: COMPARATOR
Intervention: Manual algorithm
Number of subjects: 77
Study 14684783 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit
Number of subjects: 447
Study 14684783 — intervention group
Group type: COMPARATOR
Intervention: Stroke team
Number of subjects: 447
Study 14684783 — intervention group
Group type: COMPARATOR
Intervention: Domiciliary care
Number of subjects: 447
Study 11488997 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical sampling (SA)
Number of subjects: 202
Study 11488997 — intervention group
Group type: COMPARATOR
Intervention: Lymphadenectomy (LY)
Number of subjects: 202
Study 11488997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m2, six cycles repeated every 28 days)
Number of subjects: 202
Study 10442510 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg once weekly
Number of subjects: 12
Study 10442510 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg once weekly
Number of subjects: 12
Study 10442510 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg once daily
Number of subjects: 12
Study 10442510 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 12
Study 7587033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g twice daily
Number of subjects: 240
Study 7587033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 2 g twice daily
Number of subjects: 240
Study 7587033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (various dosages)
Number of subjects: 240
Study 2262233 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 70
Study 2262233 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin
Number of subjects: 70
Study 2262233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 6769156 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 744
Study 6769156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 744
Study 31668888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 759
Study 31668888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 759
Study 31668888 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 759
Study 30572436 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 132
Study 30572436 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 132
Study 27816925 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 153
Study 27816925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 24944249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 12
Study 24944249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22067384 — intervention group
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Number of subjects: 95
Study 22067384 — intervention group
Group type: COMPARATOR
Intervention: rabbit ATG + cyclosporine
Number of subjects: 95
Study 20150021 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg every 15 days)
Number of subjects: 22
Study 18523572 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace on both ankles (intervention group)
Number of subjects: 37
Study 15718179 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended 6-month heart failure program (EP; n=62)
Number of subjects: 130
Study 15718179 — intervention group
Group type: COMPARATOR
Intervention: Standard 3-month heart failure program (SP; n=68)
Number of subjects: 130
Study 15569555 — intervention group
Group type: EXPERIMENTAL
Intervention: First questionnaire administered to first 50 randomly selected patients
Number of subjects: 100
Study 15569555 — intervention group
Group type: COMPARATOR
Intervention: Second questionnaire administered to second group of randomly selected 50 patients
Number of subjects: 100
Study 11030484 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (450 to 600 mg/day)
Number of subjects: 90
Study 11030484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 11030484 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 90
Study 8997582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 86
Study 8997582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 86
Study 8997582 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 86
Study 1308526 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rifampicin for 9 months
Number of subjects: 0
Study 1308526 — intervention group
Group type: COMPARATOR
Intervention: Standard WHO multidrug regimen (pulsed doses of rifampicin)
Number of subjects: 0
Study 6146390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 0.07 mg/kg
Number of subjects: 89
Study 6146390 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam 0.2 mg/kg
Number of subjects: 89
Study 6146390 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thiopentone 3.0 mg/kg
Number of subjects: 89
Study 6146390 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketamine 2.0 mg/kg
Number of subjects: 89
Study 6146390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 89
Study 3739803 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking allowed in low arousal condition
Number of subjects: 24
Study 3739803 — intervention group
Group type: COMPARATOR
Intervention: Smoking not allowed in low arousal condition
Number of subjects: 24
Study 3739803 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking allowed
Number of subjects: 24
Study 3739803 — intervention group
Group type: COMPARATOR
Intervention: Smoking not allowed
Number of subjects: 24
Study 31244376 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance training programme for 16 weeks, 2 sessions per week
Number of subjects: 51
Study 31244376 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study 29309578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention based on an evidence-based framework for successful CHW programmes
Number of subjects: 19
Study 29309578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive supervision and mentoring
Number of subjects: 19
Study 29309578 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of job aids, standardized manuals, and refresher training
Number of subjects: 19
Study 29309578 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalized links between clinics and CHWs
Number of subjects: 19
Study 29309578 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns raised by CHWs
Number of subjects: 19
Study 29309578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive supervision and integration with clinical services
Number of subjects: 19
Study 26458973 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous whole-body vibration (WBV) and electromyostimulation (ES)
Number of subjects: 10
Study 26458973 — intervention group
Group type: COMPARATOR
Intervention: Whole-body vibration (WBV)
Number of subjects: 10
Study 26458973 — intervention group
Group type: COMPARATOR
Intervention: Electromyostimulation (ES)
Number of subjects: 10
Study 26458973 — intervention group
Group type: COMPARATOR
Intervention: 30 s of WBV followed by 30 s of ES (WBV30/ES30)
Number of subjects: 10
Study 24903230 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiration level defined as segmented total lung volume (TLV) divided by predicted total lung capacity (pTLC)
Number of subjects: 961
Study 22217432 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (15 Hz) rTMS treatment
Number of subjects: 30
Study 22217432 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 20298557 — intervention group
Group type: EXPERIMENTAL
Intervention: Group motivational intervention (32 group sessions, 1 to 12 fortnightly, and 13 to 32 monthly)
Number of subjects: 1200
Study 20298557 — intervention group
Group type: COMPARATOR
Intervention: Usual follow up (control group) with regular visits every 3 months
Number of subjects: 1200
Study 18340565 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt diet
Number of subjects: 10
Study 18340565 — intervention group
Group type: COMPARATOR
Intervention: Medium salt diet
Number of subjects: 10
Study 18340565 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet
Number of subjects: 10
Study 18340565 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 2677TT/3435TT haplotype
Number of subjects: 10
Study 15966617 — intervention group
Group type: EXPERIMENTAL
Intervention: Televisite system used for 6 weeks after discharge
Number of subjects: 0
Study 15966617 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15966617 — intervention group
Group type: EXPERIMENTAL
Intervention: Televisite system
Number of subjects: 0
Study 12685636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrethroid-impregnated bed nets
Number of subjects: 103
Study 12685636 — intervention group
Group type: COMPARATOR
Intervention: Unimpregnated bed nets
Number of subjects: 103
Study 10896011 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with 30% body weight support (BWS)
Number of subjects: 18
Study 10896011 — intervention group
Group type: COMPARATOR
Intervention: Walking with 0% body weight support (BWS)
Number of subjects: 18
Study 8834097 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐chlorpheniramine (4 mg)
Number of subjects: 20
Study 8834097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1419592 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure with illustrations and narrative text style
Number of subjects: 100
Study 1419592 — intervention group
Group type: COMPARATOR
Intervention: Brochure with bullet-type text and no illustrations
Number of subjects: 100
Study 3831972 — intervention group
Group type: EXPERIMENTAL
Intervention: Caerulein, 1 ng/kg IV
Number of subjects: 107
Study 3831972 — intervention group
Group type: EXPERIMENTAL
Intervention: Caerulein, 75 ng/kg intramuscularly
Number of subjects: 107
Study 30785408 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic diary (e-diary) usage
Number of subjects: 89
Study 30352518 — intervention group
Group type: EXPERIMENTAL
Intervention: Online yoga intervention (60 min/week for 12 weeks)
Number of subjects: 39
Study 28446846 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (walking on treadmill, three times weekly until the end of 37 weeks of gestation) with diet control
Number of subjects: 40
Study 28446846 — intervention group
Group type: COMPARATOR
Intervention: Diet control with usual care given by obstetricians and midwives
Number of subjects: 40
Study 24518078 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 2.0 mg
Number of subjects: 46
Study 22281165 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% INCB018424 phosphate cream
Number of subjects: 0
Study 22281165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% INCB018424 phosphate cream
Number of subjects: 0
Study 22281165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% INCB018424 phosphate cream (twice a day)
Number of subjects: 0
Study 22281165 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0